Pseudobulbar affect: prevalence and management

Aiesha Ahmed
Zachary Simmons
Department of Neurology, Penn State Hershey Medical Center, Hershey, PA, USA

Abstract: Pseudobulbar affect (PBA) may occur in association with a variety of neurological diseases, and so may be encountered in the setting of amyotrophic lateral sclerosis, extrapyramidal and cerebellar disorders, multiple sclerosis, traumatic brain injury, Alzheimer’s disease, stroke, and brain tumors. The psychological consequences and the impact on social interactions may be substantial. Although it is most commonly misidentified as a mood disorder, particularly depression or a bipolar disorder, there are characteristic features that can be recognized clinically or assessed by validated scales, resulting in accurate identification of PBA, and thus permitting proper management and treatment. Mechanistically, PBA is a disinhibition syndrome in which pathways involving serotonin and glutamate are disrupted. This knowledge has permitted effective treatment for many years with antidepressants, particularly tricyclic antidepressants and selective serotonin reuptake inhibitors. A recent therapeutic breakthrough occurred with the approval by the Food and Drug Administration of a dextromethorphan/quinidine combination as being safe and effective for treatment of PBA. Side effect profiles and contraindications differ for the various treatment options, and the clinician must be familiar with these when choosing the best therapy for an individual, particularly elderly patients and those with multiple comorbidities and concomitant medications.

Keywords: pseudobulbar affect, emotional lability, depression, amyotrophic lateral sclerosis, multiple sclerosis

Introduction
Pseudobulbar affect (PBA) is characterized by uncontrolled crying or laughing which may be disproportionate or inappropriate to the social context. Thus, there is a disparity between the patient’s emotional expression and his or her emotional experience. Terminology has been varied and somewhat confusing, including involuntary emotional expression disorder, emotional lability, emotional dysregulation, pathological laughter and crying, emotional dysregulation, emotional incontinence, and emotionalism. PBA may be encountered in the setting of amyotrophic lateral sclerosis (ALS), extrapyramidal and cerebellar disorders (Parkinson’s disease, multiple system atrophy, progressive supranuclear palsy), multiple sclerosis (MS), traumatic brain injury, Alzheimer’s disease and other dementias, stroke, and brain tumors. Its impact is substantial, resulting in embarrassment for the patient, family, and caregivers with subsequent restriction of social interactions and a lower quality life. This contributes to additional disease burden in patients already impacted by a serious neurological disorder. Tateno et al noted that when compared to patients without PBA, those with PBA had a higher prevalence of anxiety symptoms and poorer social functioning. PBA has been associated with a
higher prevalence of diagnosable psychiatric disorders,\textsuperscript{5} and about 30\%–35\% of patients with PBA are depressed.\textsuperscript{6,7} PBA has also been noted to interfere with rehabilitation; a report of patients with locked-in syndrome and PBA revealed that PBA interfered with evaluation and treatment of swallowing dysfunction, the effective use of any remaining motor ability, and with attempted communication by the patient.\textsuperscript{8} Thus, recognition of this syndrome and familiarity with its treatment are important aspects of management of patients with a variety of neurological disorders, and provide the clinician with an opportunity to have a positive impact on these patients’ lives.

**Epidemiology**

The disorder occurs in association with a variety of brain disorders (Table 1).\textsuperscript{9} The range of estimates of prevalence in various neurological disorders is high, ranging from 5\% to well over 50\%, depending on diagnostic criteria, methodologies, and patient populations studied.\textsuperscript{3,10-14} In particular, the differentiation between emotional responses that are concordant with mood but exaggerated, and those that are discordant with mood, has led to substantial differences in published prevalence rates. A recent novel attempt to estimate the prevalence of PBA in the USA across six neurological disorders utilized an online survey of patients with ALS, MS, Alzheimer’s disease, stroke, Parkinson’s disease, and traumatic brain injury.\textsuperscript{15} Depending upon the scoring criteria used for the online instruments, prevalence rates ranged from 9.4\%–37.5\%, resulting in an estimated 1.8–7.1 million affected individuals in the USA. Even if the lower estimate is accepted as being the most accurate, this means that PBA is a significant national health issue in the USA, occurring in greater numbers of individuals than those affected by Parkinson’s disease, MS, or ALS.

**Pathophysiology**

The underlying mechanism in PBA appears to be a lack of voluntary control, also termed disinhibition, but the pathways are complex and are as yet incompletely understood. Detailed reviews of the widespread anatomical and neurophysiological abnormalities found by neuroimaging and neurophysiological studies in patients with PBA have been published.\textsuperscript{1,14} The cerebellum appears to play a far larger role in PBA than was hypothesized a few years ago. There are pathways from the cortex to pons to cerebellum that appear to control not only motor, but also cognitive and affective function. In support of this, patients with cerebellar lesions may demonstrate abnormalities of affect and may show emotional lability,\textsuperscript{16} and patients with multiple system atrophy – cerebellar type have a high frequency of PBA.\textsuperscript{17} One hypothesis is that the cerebellum plays a key role in modulating emotional responses so as to keep them appropriate to the social situation and to the patient’s mood based on input from the cerebral cortex. Disruption of corticopontine–cerebellar circuits results in impairment of this cerebellar modulation, causing PBA.\textsuperscript{2,14} There appears to be both sensory and motor input. A theory has been proposed in which the motor control of emotions is modulated by the cerebellum, which acts as a “gate control.” There is direct input from the motor cortex and from the frontal and temporal cortices through the brainstem which is modulated by the cerebellum. The motor input is in turn modulated by inhibitory input from the somatosensory cortex. Reduction of the inhibitory input results in disinhibition of the cerebellum, resulting in socially inappropriate or situationally disproportionate emotional expression, which is manifested as PBA (Figure 1).\textsuperscript{1,14,18} The manner in which specific cerebellar circuitry is involved in this process is the subject of ongoing investigations.\textsuperscript{14,19,20} The primary neurotransmitters believed to be involved in PBA are serotonin and glutamate. The role of serotonin in corticolimbic or cerebellar pathways may account for its impact on PBA. Glutamate is an excitatory neurotransmitter whose receptors are widely distributed within the brain. Thus, modulation of glutamatergic transmission can have widespread effects.\textsuperscript{14}

**Clinical presentation**

Clinicians are familiar with the manner in which the behavior of these patients is conveyed to them by those close to the patient. The episodes of emotion are perceived by others as being unprovoked and disconnected from the situational context, or as being out of proportion to the mood and feelings of the patient. Crying is often described as occurring in situations that are sad or otherwise emotionally touching, but which would not have produced such a striking emotional response from the patient in the past. Examples might include a sad television show, the death of a distant relative, or a show of

### Table 1 Neurological disorders most commonly associated with pseudobulbar affect

- Amyotrophic lateral sclerosis
- Extrapyramidal and cerebellar disorders
- Multiple sclerosis
- Traumatic brain injury
- Alzheimer’s dementia
- Stroke
- Brain tumors
Uncontrolled laughing may occur in situations that are only mildly amusing and may have produced a chuckle under normal circumstances. The degree of the emotional response by the patient is often striking, with crying or laughter persisting for a considerable period of time, and unable to be suppressed by the patient. In addition, laughing and crying by the patient may occur in situations that are not perceived by others as being sad or being funny. Even a discussion of PBA and those factors triggering it may be enough to result in a clear demonstration of an exaggerated emotional response. Crying appears to be a more common manifestation of PBA than laughter.

**Differential diagnosis**

The clinician may easily mistake the exaggerated and disproportionate crying seen in PBA for depression. This should not be surprising to any clinician, as the neurological disorders associated with PBA are life-changing conditions which often have a substantial emotional impact. The overlap between pathological crying and depression is complex, and the two are not entirely independent of one another in ALS. Similarly, patients with movement disorders who demonstrated PBA were found to have higher depression symptom scores and lower scores of emotional wellbeing than those without PBA, and various degrees of overlap between PBA and mood disorders have been identified in patients with stroke. Duration can be useful in distinguishing PBA from depression. Depression is of longer duration than the episodes of pathological crying characteristic of PBA – commonly lasting weeks to months in contrast to the very brief duration of PBA episodes. Both the exaggerated emotional response and the discordance between mood and emotional display are the other characteristics of PBA that are not expected with depression. PBA patients often lack the neurovegetative features of depression such as sleep disturbances and loss of appetite. There are published criteria to help differentiate PBA from depression. It is also important to distinguish PBA from bipolar disorders. Overall, the use of *Diagnostic and Statistical Manual of Mental Disorders*, Fifth Edition, criteria for the diagnosis of mood disorders, including the performance of semistructured interviews, can minimize confusion with PBA. Other neurological and psychiatric disorders within the differential diagnosis can usually be distinguished in a straightforward manner by clinicians, including various forms of epilepsy, tics, and dystonia. Drug-induced effects should also be considered in the differential diagnosis.
Diagnosis

PBA is most often judged to be present by the clinician in an informal manner, as part of his or her neurological evaluation. Criteria have been established in an attempt to define the syndrome more objectively. In 1969, Poeck defined four criteria for PBA (Table 2).\(^{25}\) Poeck’s criteria did not identify relationships with specific precipitants, although some subsequent publications have done so. These have clarified that the emotional response is not necessarily inconsistent with mood — although it may be — but the degree of the emotional response is disproportionate. A more recent set of diagnostic criteria has been proposed which emphasizes that PBA is a change from the patient’s previous emotional responses, and also provides other specific characteristics (Table 2).\(^{9}\)

PBA may be more objectively measured by published scales. The Center for Neurologic Study – Lability Scale (CNS-LS) is a seven-item self-administered questionnaire that asks about the control of laughter and crying, and has been validated in patients with ALS and MS.\(^{7,26}\) Scores range from one to five for each question, resulting in a total score of seven (no excess emotional lability) to 35 (severe excess emotional lability). A cutoff of 13 accurately predicted neurologists’ clinical diagnosis in 82% of ALS patients. Such a cutoff for patients with MS was less accurate, predicting the neurologist’s diagnosis 78% of the time in cases with low specificity, leading to a high number of false positives. Raising the cutoff to 17 for patients with MS improved the specificity without meaningfully affecting the sensitivity. The Pathological Laughter and Crying Scale (PLACS) is an interviewer-administered instrument consisting of 18 questions inquiring about sudden episodes of laughter and crying.\(^{27}\) It has been validated in patients with acute stroke, and has shown excellent interrater and test–retest reliability. Scores for each question range from zero (normal) to three (excessive emotional lability). A cutoff score of 13 yielded high sensitivity and specificity of 0.96, and resulted in a positive predictive value of 0.83. Both of these instruments have been used in studies of treatment of PBA, as described below.

In practice, PBA is likely underdiagnosed, perhaps because of confusion with depression and other neurologic and psychiatric disorders. Although the merits of online surveys can certainly be debated, it is striking that one such survey found that only 41% of those who were identified as having PBA by the survey and who discussed their emotional responses with their physician were diagnosed by that physician as having PBA, and only 52% of those received a prescription for treatment.\(^{15}\)

Treatment

General principles

The goal of treatment of PBA is to diminish the severity and frequency of episodes. The targets of treatment are primarily norepinephrine, serotonin, or glutamate, using tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and, most recently, the cough suppressant dextromethorphan. Historically, dopaminergic medications such as levodopa and amantadine have been used as well, but with lower response rates.\(^{28}\) The serotonergic action of SSRIs and TCAs appears to be the most significant therapeutic mechanism in treatment of PBA, via an increase in availability of serotonin at the synapses in corticolimbic and cerebellar pathways. SSRIs have a relatively narrow mechanism of action, directed toward enhancing serotonergic function, whereas TCAs alter a broader range of neurotransmitter functions.

In contrast to SSRIs and TCAs, dextromethorphan inhibits glutamatergic neurotransmission via actions at a variety of locations including N-methyl-D-aspartate receptors and \(\sigma\)-1 receptors.\(^{29}\) In administering dextromethorphan as monotherapy, there is rapid and extensive conversion by the liver to a related compound which is unable to cross the blood–brain barrier. This results in extremely low plasma concentrations of dextromethorphan even with the administration of very high oral doses. Blockade of hepatic metabolism can be accomplished by the concurrent administration of the cardiac antiarrhythmic drug quinidine sulfate,\(^{30}\) leading to higher and sustained plasma concentrations of dextromethorphan at a fraction of the dose required if quinidine sulfate was not used.

Until recently, all treatments have, of necessity, been off-label. Four major uncontrolled trials of antidepressants

---

Table 2 Diagnostic criteria for pseudobulbar affect

<table>
<thead>
<tr>
<th>Poeck(^{25})</th>
<th>Cummins: necessary elements of the episodes(^{9})</th>
</tr>
</thead>
<tbody>
<tr>
<td>The emotional response is situationally inappropriate</td>
<td>A change from previous emotional responses</td>
</tr>
<tr>
<td>The patient’s feelings and the affective response are not closely related</td>
<td>Inconsistent with or disproportionate to mood</td>
</tr>
<tr>
<td>The duration and severity of the episodes cannot be controlled by the patient</td>
<td>Not dependent on a stimulus, or are excessive relative to that stimulus</td>
</tr>
<tr>
<td>Expression of the emotion does not lead to a feeling of relief</td>
<td>Cause significant distress or social/occupational impairment</td>
</tr>
<tr>
<td>Not accounted for by another psychiatric or neurologic disorder</td>
<td>Not due to a drug</td>
</tr>
</tbody>
</table>
in PBA all used SSRIs and reported favorable outcomes (Table 3), although the severity scales used as outcome measures were unvalidated.6,24,30,31 Pioro recently published a review of the treatment of PBA in which he identified 22 published case reports or therapeutic trials of at least five patients from 1980 through to 2010.24 He identified ten randomized, double-blind studies with placebo controls. Six of them used some form of a severity scale and had 20 or more patients (Table 4).27,33–37 The others used clinical judgment and/or patient-reported episode rates and had fewer than 20 patients. The response to active treatment either with an antidepressant or dextromethorphan/quinidine was greater in all placebo-controlled trials than the response to placebo. The efficacy of antidepressants appears to be unrelated to the treatment of depression, based upon several pieces of evidence: 1) the onset of action may occur within a few days, which is faster than expected for depression; 2) doses are lower than those usually used to treat depression; and 3) most patients with PBA are not depressed.6,7

In October 2010, the US Food and Drug Administration (FDA) approved Nuedexta® (Avanir Pharmaceuticals, Aliso Viejo, CA, USA) for the treatment of PBA, making this the first FDA-approved drug for this indication. This compound contains dextromethorphan 20 mg and quinidine 10 mg, thus taking advantage of the blockade exerted by quinidine on the first-pass hepatic metabolism of dextromethorphan. Approval was granted on the basis of a large randomized, placebo-controlled trial in 326 patients with MS or ALS who had clinically significant PBA (Table 4). The treated group of patients demonstrated only about half as many laughing and crying episodes as were recorded in the placebo-treated cohort.35

**Specific recommendations**

When determining which treatment to select, the clinician must consider tolerance and the potential for adverse effects as major factors. TCAs, with their broad effects on monoaminergic, cholinergic, and histaminergic neurotransmission, may produce a wide range of side effects including dry mouth, constipation, orthostatic hypotension, confusion, sedation, and potential cardiotoxicity. The elderly often tolerate TCAs particularly poorly. However, TCAs may facilitate sleep if given as a nighttime dose. Also, their anticholinergic properties make them useful for control of salivation in patients such as those with bulbar ALS in whom this may be particularly troublesome. The actions of SSRIs, being largely limited to the enhancement of serotonergic function, generally have a much more limited side effect profile, resulting in a much lower rate of discontinuation.24,38 Of course both SSRIs and TCAs can be used to treat concomitant depression, although the physician should be attuned to the higher doses and longer time frames usually needed for the treatment of depression as compared to PBA.

Dosing ranges are broad, but the average dose of SSRIs in clinical trials for the treatment of PBA was 20 mg/day for fluoxetine and citalopram and 50 mg/day for sertraline.14 Not unexpectedly, these are at the low end of the range usually used for treatment of depression. The commonly used TCAs are nortriptyline and amitriptyline, usually at dosages from 20–100 mg/day.27,39 and usually given as a single bedtime dose to minimize adverse effects and maximize tolerability.

There is more limited clinical experience with dextromethorphan/quinidine because of the relatively recent

---

### Table 3 Uncontrolled trials of selective serotonin reductase inhibitors in pseudobulbar affect

<table>
<thead>
<tr>
<th>Drug</th>
<th>Disease</th>
<th>Number of subjects</th>
<th>Main findings</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluoxetine</td>
<td>MS or stroke</td>
<td>13</td>
<td>Reduced episode rate</td>
<td>30</td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>TBI or stroke</td>
<td>6</td>
<td>Reduced severity on unvalidated scale</td>
<td>31</td>
</tr>
<tr>
<td>Fluvoxamine</td>
<td>ALS, MS, or stroke</td>
<td>10</td>
<td>Reduced episode rate</td>
<td>32</td>
</tr>
<tr>
<td>Paroxetine, citalopram</td>
<td>TBI</td>
<td>26</td>
<td>Reduced severity on unvalidated scale</td>
<td>6</td>
</tr>
</tbody>
</table>

**Abbreviations:** ALS, amyotrophic lateral sclerosis; MS, multiple sclerosis; TBI, traumatic brain injury.

### Table 4 Placebo-controlled trials of medications in pseudobulbar affect

<table>
<thead>
<tr>
<th>Drug class</th>
<th>Drug</th>
<th>Disease</th>
<th>Number of subjects</th>
<th>Main findings</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>TCA</td>
<td>Nortriptyline</td>
<td>Stroke</td>
<td>28</td>
<td>Reduced severity on validated scale (PLACS)</td>
<td>27</td>
</tr>
<tr>
<td>SSRI</td>
<td>Fluoxetine</td>
<td>Stroke</td>
<td>20</td>
<td>Reduced severity on unvalidated scale</td>
<td>33</td>
</tr>
<tr>
<td>SSRI</td>
<td>Sertraline</td>
<td>Stroke</td>
<td>28</td>
<td>Reduced lability on unvalidated scale</td>
<td>34</td>
</tr>
<tr>
<td>SSRI</td>
<td>Fluoxetine</td>
<td>Stroke</td>
<td>106</td>
<td>Reduced crying on unvalidated scale</td>
<td>35</td>
</tr>
<tr>
<td>Antiglutamatergic</td>
<td>DMQ</td>
<td>MS</td>
<td>150</td>
<td>Reduced severity on validated scale (CNS-LS)</td>
<td>36</td>
</tr>
<tr>
<td>Antiglutamatergic</td>
<td>DMQ</td>
<td>ALS or MS</td>
<td>326</td>
<td>Reduced severity on validated scale (CNS-LS)</td>
<td>37</td>
</tr>
</tbody>
</table>

**Abbreviations:** ALS, amyotrophic lateral sclerosis; CNS-LS, Center for Neurologic Study – Lability Scale; DMQ, dextromethorphan/quinidine; MS, multiple sclerosis; PLACS, Pathological Laughter and Crying Scale; SSRI, selective serotonin reductase inhibitor; TCA, tricyclic antidepressant.
FDA approval. However, the most common side effects are dizziness, diarrhea, falls, headache, nausea, fatigue, nasopharyngitis, constipation, and dysphagia. At the dose contained in the approved compound, quinidine did not demonstrate adverse cardiac effects.24,27 The American Academy of Neurology published guidelines in 2009 which recommended that dextromethorphan/quinidine “should be considered for treatment of PBA in patients with ALS, if approved by the FDA and if side effects are acceptable.”12 Updated guidelines have yet to be issued. The FDA-approved dosing is one capsule daily for 7 days, followed by an increase to one capsule every 12 hours.

Conclusion
PBA can impact quality of life and disease burden in patients with many commonly encountered neurological disorders, independent of disturbances of mood. Although the mechanisms are not fully understood, serotonergic and glutamergic transmission appear to play major roles, and there are clear therapeutic benefits in treatment with SSRIs, TCAs, or with dextromethorphan/quinidine. By managing PBA with an appropriate pharmacologic approach, clinicians can have a meaningful impact on symptoms that are socially embarrassing and functionally limiting for these patients.

Disclosure
The authors report no conflicts of interest in this work.

References
24. Ahmed and Simmons

Dovepress

Therapeutics and Clinical Risk Management 2013:9

submit your manuscript | www.dovepress.com

Dovepress

488

Dovepress